Arovella Therapeutics Ltd has released a press release.
SUDA Appoints Dr Michael Baker CEO
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Case For Share Consolidation and Appendix 3A.3
- SUDA Finalises Agreement With Cann Pharmaceutical
- Response to ASX Query regarding Accounts
- Manaing Director and CEO Resignation
- ArTiMist Appeal Lodged With TGA
Later from Arovella Therapeutics
- SUDA Signs Co-Development Deal With Ordesa
- SANOFI and SUDA Entered Into A Feasibility Agreement
- Half Yearly Report and Accounts
- SUDA Signs Additional Licence With Mitsubishi Tanabe
- Anagrelide Cancer Patent For Japan
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics